drugset / Trial / NCT02456896

Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder

NCT02456896

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The present study has been designed to evaluate the change in serum BDNF level with oxcarbazepine monotherapy in bipolar disorder and to explore the possibility of its neuroprotective effect.

Timeline

Start
2015-06
Primary completion
2015-12
Completion
2015-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxcarbazepine Small molecule 900 mg

Indications